FORTREA EXPANDS EXECUTIVE TEAM, APPOINTING OREN COHEN AS CHIEF MEDICAL OFFICER AND SCOTT DOVE AS PRESIDENT OF CLINICAL PHARMACOLOGY SERVICES

DURHAM, N.C., Feb 19 (Bernama) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea’s portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea’s early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea’s Executive Committee.

“The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients,” said Anshul Thakral, CEO. “Working closely with our business leaders across all phases of clinical development, Oren will deepen his relationships with clients. He’s engaging earlier in scientific dialogue and collaborating closely with our physicians and therapeutic leaders to help address complex development challenges, all while upholding the highest standards of scientific integrity and patient safety. Scott is making a fast start with our Clinical Pharmacology team and is getting a first-hand view of our world-class clinics. He combines a strong technical background in clinical development and operations with a successful track record of leadership in building and leading global organizations, and I’m looking forward to his insights on how we further strengthen our offering.”